Close

Pharmacyclics (PCYC) Reports Update on BTK Inhibitor, Additional Preclinical Work Required

February 27, 2015 2:49 PM EST Send to a Friend
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase (BTK) inhibitor for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login